TCF20 and neoplasm: To assess the triple combination therapy in an additional KP lung tumor model, we treated 393P tumors that acquired resistance to selumetinib as previously characterized7 (393P-AR1) with the identical treatment groups and observed a significant decrease in tumor growth only with treatment of the triple combination therapy (Fig. 6d, e).